Die psychische Wirkung der mexikanischen Droge „Ololiuqui“ am Menschen. Heim, E., Heimann, H., Lukács, G. 1968. Psychopharmacologia, 13, 35–48. 10.1007/BF00401617
Translated from German by Claude.
The Psychological Effects of the Mexican Drug "ololiuhqui" on Humans
E. Heim, H. Heimann, and G. Lukács
Psychiatric University Clinic Waldau-Bern (former Director: Prof. M. Müller)
Clinical-Psychological Laboratory (former Director: Prof. H. Heimann)
Received August 31, 1967
Final version: February 2, 1968
Psychotomimetic Effects of the Mexican Drug "ololiuhqui"
Summary. The alkaloids of the third magic Mexican drug "ololiuhqui" — chemically closely related to LSD 25 — were studied in normal subjects in a laboratory situation. A standardized method (developed and applied before in testing other psychotomimetic drugs) included the following procedure: A short interview taken every 45 min was recorded on sound-film and then analyzed for changes in expression and motor behavior. A battery of psychometric tests also given every 45th minute was studied for trend-changes over time. Finally, symptoms reported by the subjects were divided into 8 categories, reflecting a spectrum going from autonomic side-effects to psychotic symptoms and alteration of consciousness.
The results indicate that the effect of the two major compounds, d-lysergic-acid-amide and d-iso-lysergic-acid-amide, determine the effect of the total alkaloids of ololiuhqui. With d-lysergic-acid-amide the clinical picture was one of intoxication with strong autonomic side-effects; with d-iso-lysergic-acid-amide euphoria, synesthesia, and altered time experience were observed. In small doses the response to total-alkaloids resembled that of d-iso-lysergic-acid-amide; in higher doses it resembled that of d-lysergic-acid-amide, i.e. a heavy intoxication with reduced consciousness and autonomic side-effects. Overall, there was little difference between the total alkaloids and the compounds of ololiuhqui.
Psychometric tests taken at each 45-min-phase also reflected the progressive intoxication: the performance in each of the five tests measuring the ability to concentrate was increasingly reduced, as compared to placebo subjects, during the time of observation. This is in contrast to observations on Psilocybin: here the psychometric results were worst after the first 45-min-phase, whereas changes in expression and motor behavior were greatest in the last of the phases, i.e. after 2–3 hours.
Not only are there no phase-dependent alterations with qualitative modification of the effects in ololiuhqui as compared with Psilocybin; in addition there was little evidence of typical alteration in consciousness and hallucinations as typically seen with psychotomimetic drugs like LSD 25 and Psilocybin.
In conclusion, ololiuhqui tested in normal subjects in a standard laboratory situation lacks the characteristics of the typical psychotomimetic drugs. It resembles more drugs like scopolamine and ibogalin, inducing a toxic psychosis.
Key Words: Lycergic Acid Diethylamide — Psilocybine — Psychological Interview — Psychometrics — Toxic Psychoses.
1. Research Question
Little verified information has previously been known about the psychological effects of "ololiuhqui," the third Mexican magic drug. The Spanish authors who described the use of the drug by the indigenous peoples in the 16th and 17th centuries mention that ololiuhqui numbs and confuses the senses (Bernardino de Sahagun), and that it leads to intoxication with phantasmal visions and demonic apparitions (Francisco Hernandez). Reko counted it among the magical poisons of the indigenous peoples and described a predominantly sedating effect. The identification of the plant called Serpent's Herb (cox-xihuitl) by the indigenous peoples was accomplished by Urbina and confirmed by Schulthes. It concerns the convolvulaceous species Rivea Corymbosa and Ipomea violacea. Hofmann and colleagues isolated six indole alkaloids from the seeds of these plants in 1960 and determined their chemical structure. Phytochemically surprising was the fact that such alkaloids — previously isolated only from lower fungi of the genus Claviceps — were demonstrated here for the first time in a higher plant.
Moreover, most of the ololiuhqui alkaloids had previously been produced semi-synthetically in the Sandoz laboratories, and they bear a close relationship to the phantasticum LSD 25.
The following alkaloids were isolated by Hofmann and colleagues (Fig. 1).
Little research has previously been conducted on the effects on humans. Solms found, using the semi-synthetic d-lysergic acid amide at doses of 0.75–1.0 mg s.c., lack of drive, indifference, need for sleep, and increasing clouding of consciousness, which after ½–1 hour transitioned into an arousable sleep that can last approximately 2 hours. He was unable to observe hallucinatory phenomena, though rather unpleasant neurovegetative disturbances occurred (hypersalivation, vomiting, dizziness, diarrhea). According to Osmond, the unchewed seeds have no effect (self-experiment by Reko). Osmond found, at a dose of 100 carefully chewed seeds of Rivea corymbosa, clear psychological changes: initially social withdrawal, apathy, and drowsiness, accompanied by a certain fascination with objects in the immediate surroundings, then drowsy sleep, which after several hours transitioned into a prolonged sense of wellbeing. Osmond's dosage amounted (according to our calculation) to a maximum of approximately 2.8 mg total alkaloids.
Our study aims to answer two questions:
1. How do the effects of the three main alkaloids compare with one another and with an artificial alkaloid mixture of all the drug's alkaloids in a concentration ratio corresponding to their natural occurrence?
2. Can psychodysleptic phenomena be produced in humans through a careful increase in dose, which can be compared with the effects of Psilocybin?
[FIGURE: Fig. 1 — Chemical structure diagrams of five alkaloids found in ololiuhqui with their percentage compositions: D-Lysergic acid amide 45%, D-Isolysergic acid amide 25%, Elymoclavine 5%, D-Lysergol 5%, Chanoclavine 10%]
Fig. 1. The alkaloids contained in ololiuhqui with indication of the percentage share according to Fanchamps (not shown: Ergobasine 10%)
2. Methods
We used the method developed by Heimann (1961) for the study of psychopharmaceuticals in healthy test subjects, which allows precise recording of the induced changes on three levels of psychological life, namely on the level of expression and behavior, of experience, and of psychological performance. The method allows for a subsequent reconstruction of the experimental procedure and a comparison of temporally corresponding findings:
The test subjects (ten physicians who volunteered) are situated with the examiner in an artificially lit room. The examiner can operate, via remote control, a sound-film camera and a tape recorder set up in an adjacent room, and in this way record expression and behavior as well as the subjects' experiential reports at fixed time intervals. At the same intervals, the subject must carry out a series of performance tests. The film, tape recording, and test recordings take place before administration of the substance, and at 45, 90, 135, and 180 min after administration. In this way, four cross-sections of changes on the three psychological levels are captured.
The sound films are evaluated descriptively according to expressional-phenomenological criteria established by Heimann,
1 with regard to changes in facial expression, posture, and gesture, as well as verbal expression.
From the experiential reports recorded on tape, predetermined symptoms were counted, so that for each substance and for the total alkaloids a symptom distribution grouped by category
2 could be established.
The following table provides information about the experiments conducted with individual substances and the total alkaloid mixture, and the doses administered (administration was carried out in aqueous solution orally):
Table. Overview of Test Subjects
| Subject | Age | Weight | Dose absolute (mg) | Dose/kg BW (mg) |
|---|
| D-Lysergic acid amide | E. H. | 33 | 74 | 3 | 0.04 |
| S. B. | 35 | 75 | 6 | 0.09 |
| D-iso-Lysergic acid amide | D. B. | 30 | 58 | 2 | 0.03 |
| F. D. | 34 | 72 | 4 | 0.06 |
| P. S. | 27 | 75 | 5 | 0.07 |
| Lysergol | L. C. | 34 | 72 | 2 | 0.03 |
| H.W.I. | 29 | 72 | 4 | 0.06 |
| E. H. | 33 | 74 | 6 | 0.08 |
| L. G. | 30 | 72 | 8 | 0.11 |
| Total alkaloids | B. S. | 29 | 98 | 2 | 0.02 |
| J. H. | 34 | 54 | 3 | 0.06 |
| J.P.P. | 21 | 75 | 6 | 0.08 |
| E. H. | 33 | 74 | 7 | 0.10 |
After 13 experiments we discontinued the study, because at the higher doses used by us, very unpleasant neurovegetative intoxication symptoms were consistently observed.
3. Results
a) d-Lysergic Acid Amide
Expression and behavior of the test subjects changed as early as 45 min after ingestion of the substance: the subjects appeared to be suffering, their facial expressions deteriorated as if after a serious illness, their movements were markedly slowed. The speaking voice showed a decrease in volume, pitch, melody, dynamics, and tempo. In the subsequent examination cross-sections these changes intensified, so that the subjects ultimately appeared drowsy and apathetic. Subject E.H., who had taken 3 mg (= 0.04 mg per kilogram of body weight), recovered after approximately 3–4 hours; Subject S.B., who took 6 mg (= 0.09 mg per kilogram of body weight), had to go to bed following an injection of an anti-nausea medication and did not recover until the following day. In the self-reports of both subjects, complaints about vegetative symptoms predominated: unpleasant, flu-like feeling of illness, nausea, suddenly shooting nausea reflex with vomiting, which could be controlled with 2 cm³ Cyclicinum hydrochloricum. In addition, sensations of heat, sweating, dizziness, feelings of heaviness, and general fatigue were observed. Subject S.B. (6 mg) awoke in the middle of the night with precordial pain and shortness of breath and simultaneously suffered from intense unmotivated anxiety. Thought disturbances, changes in mood (apart from a marked dysphoria), and significant alterations of consciousness were absent.
b) d-Isolysergic Acid Amide
Expression and behavior of the subjects changed in the first examination cross-section in the direction of a drowsily sunken state, from which they could be easily recalled into an engaged and present posture by being addressed. In the following examination cross-section they showed relaxation and a contented, not lifeless facial expression. In the fourth and fifth examination cross-sections, however, they appeared to be suffering, listless to drowsily dazed. The speaking voice showed, during the second through fifth examination cross-sections, a reduction in dynamics, melody, and pitch, while volume and tempo, after an initial reduction, regained their initial values in the last three examination cross-sections.
The results of the experiential accounts parallel the changes in expression: after a relatively brief phase of drowsiness, all subjects felt relaxed and comfortable, in some cases even somewhat euphoric. They seemed to overestimate their capacity for performance. Noted were paresthesias and individual synesthesias, as well as an overestimation of elapsed time. In the fourth and fifth examination cross-sections they complained of difficulty thinking and a poverty of ideas.
In subject P.S. (5 mg), after 3½ hours there was a sudden onset of severe nausea with a drop in blood pressure, which could be controlled with analeptics and anti-nausea medication after approximately 30 min. Simultaneously, the subject experienced a feeling of total annihilation and fear of death, which subsided after vomiting approximately 60 min later, but did not fully resolve until the course of the night.
c) d-Lysergol
Changes only occurred at a dosage of 8 mg, with a clear slowing visible in expression and behavior. Facial expression appeared flat and speech showed a reduction in the five expressive qualities.
Subjectively, fewer vegetative sensations were observed, but a clear inhibition of initiative was present.
d) Total Alkaloids
At low doses (subject B.S., 2 mg), the film analysis showed a drowsy, listless posture in the first cross-section, but in the second cross-section a euphoric relaxation. The previously restrained facial expression changed into a more extroverted conviviality with inappropriate laughter. In the fourth and fifth examination cross-sections this was most pronounced, and the euphoria did not subside until 5–6 hours after ingestion of the substance. From the self-report:
"After approximately 45 min, vegetative discomforts appeared, above all nausea and retching. After approximately 90 min relaxation occurred and the disturbing physical sensations disappeared. Gradually I felt an increasing sense of not caring and euphoria, as well as a pleasant fatigue. At the same time a feeling of heaviness in the head and extremities appeared, which was not experienced as unpleasant. A reduction in critical thinking occurred and a positive acceptance of general passivity. On the whole I had the feeling of a mild intoxication, but compared with alcohol, more euphoria. The sobriety of the surroundings had a disturbing effect.
Approximately 4 hours after the start of the experiment I returned home, where my wife spontaneously declared me tipsy. This mild state of intoxication with clear ataxia lasted approximately 2 more hours and subsided without any hangover feeling. The following night I slept well.
Throughout the entire experiment I was unable to observe any changes in visual experience and also no sensory illusions in other sensory domains."
At higher doses, the unpleasant vegetative discomforts predominated. The experiment with 7 mg (= 0.097 mg per kilogram of body weight) took a rather dramatically toxic course: at the first examination cross-section after 45 min the subject already appeared markedly affected, exhausted, and depressed. Facial expression and gestures were considerably slowed. In the following examination cross-sections the slowing increased and facial expression and speech became flatter. All expressive qualities of speech were diminished, particularly dynamics and tempo. A blurring of articulation also occurred. The subject appeared apathetic and mildly clouded in consciousness. When addressed, the subject responded with a marked delay. During performance tests, sighing breathing was observed. Left to their own devices, the subject immediately sank back into the consciousness-clouded state.
3 hours and 40 minutes after the start of the experiment, a sudden vegetative shift occurred. Within a few minutes the subject became hyperalert and simultaneously showed a pronounced anxious tension. The previously unchanged blood pressure rose to 150/100, the pulse from 72 to 100. Strong pulsations of the abdominal aorta were remarkably visible through the clothing. Breathing became shallow, its frequency fell. The subject expressed fear of death, the facial expression became increasingly pale and deteriorated. A strong mydriasis was noted. Respiratory and circulatory conditions were not, however, dangerously altered; the subject was awake and responsive. This made the subjective expectations of death all the more starkly contrasting. 4 hours after ingestion of the substance, the subject received 4 cm³ Promazine, after which the subject calmed down and fell asleep. Elevated blood pressure and pulse returned to normal values within 1 hour. ½ hour after the Promazine injection, violent projectile vomiting occurred from sleep. 7 hours after the start of the experiment the subject could gradually be awakened and brought home in a drowsy state.
Self-Report of This Experiment
"Already approximately 30 min after ingestion of the substance, some apathy and general heaviness. Conversation with the experimenter already impaired due to increasing inhibition of drive. No vegetative discomforts. After 1 hour, completely drive-less staring into space. Disinterested in all conversation, entire body paralyzed by an unpleasant nonspecific fatigue. After 1½ hours no signs of nausea whatsoever. Instead, an unbearable leaden feeling of heaviness throughout the entire body, particularly intense as a pulling pain in the neck. Slightly ataxic gait. Great indifference toward the surroundings and the experimental situation. A conversation outside the experimental room is fully registered as a sequence of words and melody, but the content of the conversation goes unheeded. Individual words stimulate visual images. Clear, organized thinking is increasingly impaired. Later the test tasks become almost impossible to solve. Speaking and other tasks can only be accomplished after laborious self-collection. As soon as no one is engaging with me, I sink into apathy. At times I find myself in a half-sleep. I have the feeling that time has slowed down. After approximately 3 hours I must lie down, as I can no longer endure the tormenting feeling of heaviness in my body. At this point strange synesthesias occur, in which bodily posture is translated into visual images. A bent arm appears, for example, as an angled, bordered hollow arrow, which is optically hallucinated. Approximately 3½ hours after the start of the experiment I have an indescribable feeling of wretchedness and weakness, without nausea. Breathing is labored. I feel dried out and fear fainting. Suddenly I am wide awake, present, perceiving the personal and external situation very precisely, but deeply worried about my physical state. I fear that the poisoning by the substance is becoming uncontrollable. The experimenter's account of a similar experience in an LSD experiment reassures me for only a brief time. I have the feeling of increasingly deteriorating, and believe I can maintain the shallowing breathing only through iron will. My pulse is hammering throughout my body, especially in my head, which is barely tolerable. Suddenly I am convinced that I must die, whereby thoughts of my family recede entirely behind the vital anxieties about my momentary condition. I try to resist the Promazine injection, because I fear that willful control over the shallowing breathing will be completely lost. After the injection, the severe anxiety gradually subsides as I simultaneously doze off. I experience the unexpected vomiting as a relief. After waking and during the following 12 hours, light physical exertion (climbing stairs, sitting up in bed) immediately brings on the pulse hammering with corresponding anxiety. Only 48 hours after the start of the experiment have I fully recovered."
The two experiments with 3 and 6 mg, resp. 0.055 mg per kilogram and 0.080 mg per kilogram of body weight, lay in terms of expression and behavior between the two described experiments of subjects B.S. and E.H.
e) Symptom Distribution
In the following Fig. 2, the symptom groups are plotted graphically according to the stated frequency for the partial substances and the total alkaloids. We have added together the individual statements from each examination cross-section, on the assumption that questioning in the temporally corresponding examination cross-sections was comparable, and that a symptom reported four times, for example, carries more weight than if it occurred only once. In doing so, because of the unequal number of subjects observed per experiment, the values were each recalculated to one subject.
When comparing the individual alkaloids, it is immediately apparent that d-lysergic acid amide produces the most vegetative sensations, and that the other symptom groups recede markedly with this substance. With d-iso-lysergic acid amide, vegetative sensations are less frequent; instead, stronger disturbances of thinking, affect, and consciousness appear here. Lysergol shows the least subjective changes. When comparing the enumerated symptoms of the total alkaloid effect with those of the individual alkaloids, it is notable that the total alkaloids in their subjective effects represent a combination of the individual alkaloids, and that no new qualitative effects are therefore to be expected from the three alkaloids not individually tested (elymoclavine, chanoclavine, ergobasine) or from the combined application of the alkaloids tested by us.
[FIGURE: Fig. 2 — Four bar charts showing symptom distribution for Lysergic acid amide, Iso-Lysergic acid amide, Lysergol, and ololiuhqui (Total alkaloids), each with categories A through H on the x-axis]
Fig. 2. A Vegetative sensations;
B Motor function;
C Perceptual disturbances;
D Sense of touch, deep sensation; Body schema;
E Spatial-temporal experience;
F Thinking;
G Affect;
H Consciousness
f) Performance Tests
In Fig. 3, the mean values of the individual examination cross-sections for the five performance tests used by us are plotted. They are set in relation to a group of subjects who received Psilocybin (N = 24) under the same experimental conditions, and a placebo group (N = 100), so that a statistical comparison between the ololiuhqui subjects (all results of the partial substances and the total alkaloids combined) with Psilocybin and placebo is made possible. The statistical analysis was carried out for the concentration test using Meili's t-test, and for the other tests using non-parametric methods (Mann and Whitney test).
Meili Test. The placebo subjects show a practice gain in all examination cross-sections. The greatest differences appear in the first examination cross-section, 45 min after ingestion of the substance. Here the ololiuhqui subjects show a practice gain not significantly different from the placebo group, while the Psilocybin group shows the strongest impairment of concentration, specifically a slowing that is significant compared with both of the other groups. In the second examination cross-section and in the subsequent ones — i.e., with increasing intoxication — the ololiuhqui subjects fall behind the placebo group and increasingly resemble the values of the Psilocybin group (in the 3rd hour no longer significantly different from them). The comparison of the Psilocybin effect and the ololiuhqui effect with the behavior of the placebo subjects thus shows that the maximum of concentration impairment for Psilocybin lies in the first, and that for ololiuhqui in the last examination cross-section.
[FIGURE: Fig. 3 — Line graphs showing performance test results across examination cross-sections for five tests: Meili Test, Rey Test, Word enumeration with specific initial letters, Forward digit span, and Backward digit span, comparing Psilocybin and ololiuhqui groups against placebo]
Fig. 3. Effect of Psilocybin and ololiuhqui. — — — without medication; —— Psilocybin; — · — ololiuhqui
Visual-Motor Concentration Test according to Rey. The ololiuhqui subjects differ here in all examination cross-sections not only from the placebo group, but are also significantly less impaired than the Psilocybin group.
Word Enumeration with Specific Initial Letters during 30 min. In this test as well, the results of the ololiuhqui group lie between those of the placebo and the Psilocybin subjects. The latter show a stronger impairment of this performance in all four examination cross-sections under substance effect. The ololiuhqui subjects improve their performance in the last two examination cross-sections despite increasing intoxication, so that the results taken together, compared with those of the Psilocybin group, are significantly better. Under ololiuhqui, word availability is similarly, though less markedly, disturbed throughout the entire observation period than under Psilocybin.
Forward Digit Span. Apart from a mildly significant reduction in the third examination cross-section of the ololiuhqui subjects, we find neither with Psilocybin nor under ololiuhqui a significant impairment of purely mnestic performance.
Backward Digit Span. Here we found significantly lower performance in all examination cross-sections for the ololiuhqui subjects compared with the placebo group (weakly confirmed in the first three examination cross-sections, strongly confirmed in the last).
In summary, it can be stated regarding the results of the performance tests that predominantly concentrative performance and word availability are disturbed by both substances, but in different ways.
Discussion
The comparison of the effects of the partial alkaloids and their combinations shows strikingly few differences. In all cases we obtained mild to moderately severe intoxication states, which at higher doses persisted beyond the three-hour observation period and are characterized by a predominance of unpleasant vegetative sensations. These made the experiments extremely distressing for the subjects as a rule and led us to limit the study to a relatively small number of experiments.
3
The analysis of expressive phenomena and behavior shows primarily these progressive changes in wellbeing: mood shifts mostly in the direction of dysphoria, at low doses occasionally of euphoria, and reduction of vigilance. At higher doses, slowing of motor behavior, expressive movements and speech, and drowsy apathy are observed. These and a delay in readiness to react indicate that clouding of consciousness is primarily present. Differentiation between the effects of the individual alkaloids was, given the small number of experiments, only possible on the level of experience with the help of a symptom distribution. Here d-lysergic acid amide showed fewer vegetative but stronger changes in thinking, affect, and consciousness. The symptom distribution of the total alkaloids indicates that a combination of the tested individual alkaloids is present here, and that the untested alkaloids or the combination of the alkaloids tested by us produce no new qualitative effects.
Our first question can therefore be answered by saying that the alkaloids tested by us and the total alkaloid mixture differ only insignificantly from one another in their effects.
In contrast to Psilocybin (Heimann, 1961, 1965), we find under ololiuhqui no qualitative modification with phase-by-phase progression. Rather, there exists a progressive intoxication, which is demonstrable both in expression and behavior and in an impairment of concentrative performance. Here there exists a
parallelism between psychological performance impairment and the objectively detectable changes in expression and behavior, in contrast to the
phase shift of the two observed criteria under Psilocybin (maximum impairment of concentration ability in the first examination section, where expression and behavior are only slightly impaired; maximum of expressive changes in the third examination section, where the results in the concentration tests are already approaching baseline values). As we have set out elsewhere, the progression of effects of model psychoses in the narrower sense
4 thus shows a qualitative modification dependent on the duration of the drug's action, which can however only be demonstrated using a research methodology that takes temporal relationships into account (Heimann, 1961).
ololiuhqui differs fundamentally from the previously known phantastica also in that only very few perceptual disturbances occurred; in particular, optical hallucinations were almost entirely absent. The other reported symptoms as well, e.g., changes in time experience, body schema, loosening and impoverishment as well as slowing of the flow of thought, and the mood changes, are relatively discreet — in any case by no means as pronounced as with LSD 25 or Psilocybin. They belong in the category of what one can observe with mild somnolence and nonspecific intoxication. Our results agree with the findings of the studies by Isbell and Gorodetzky, who were able to observe only clouding of consciousness without hallucinations using extracts from ololiuhqui seeds and a synthetic alkaloid mixture of ololiuhqui alkaloids.
When we ask which other substances produce similar intoxications to those caused by the ololiuhqui alkaloids tested by us, we can highlight a certain similarity with the scopolamine effect, which likewise exhibits psychomotor slowing, mild clouding of consciousness, and hypnagogic phenomena (Heimann, 1952). Furthermore, studies with the alkaloid ibogalin (active ingredient from the Apocynaceae Tabernanthe iboga) using the same research methodology have yielded an intoxication state comparable to ololiuhqui without significant productive symptomatology and with mild sedation (Schmid, 1967).
The question arises whether the alkaloids of ololiuhqui are present in the seeds and in the drug itself perhaps in a different form, so that the effect of the total drug might differ from the alkaloids tested by us. Supporting this hypothesis is the recent isolation by Hofmann of a substance closer to LSD 25: d-lysergic acid hydroxy-ethylamide (Cerletti and Hofmann). In his view, it is split through the extraction processes in alkaline medium into the lysergic acid amide tested by us and acetaldehyde.
5 Against this, however, is the fact that the effect which Reko described among the indigenous peoples, and the observations by Osmond with chewed seeds of Rivea corymbosa, fit quite well with the phenomena observed by us. Our experiments with d-lysergic acid amide also confirm the results which Solms had obtained with this substance, namely a predominantly sedating intoxication.
When the descriptions by Spanish authors of demonic apparitions under the effect of ololiuhqui are discussed, this need not necessarily involve hallucinations similar to those of the Psilocybin effect; rather, cultural and racial factors could be responsible. Visions in the context of cultic activities, even under the effect of drugs, i.e. through a pharmaceutically reduced vigilance, can be psychogenic. It is therefore plausible to attribute the differences in effect between the laboratory experiment and the descriptions in historical sources to these nonspecific factors. Additionally, there is the possibility that the indigenous peoples possess a greater tolerance for vegetative disturbances, so that these recede in experience.
References
Cerletti, A., and A. Hofmann: Personal communication.
Fanchamps, A.: La psychopharmacologie moderne et les drogues magiques mexicaines. Rev. méd. Suisse rom.
82, 15–31 (1962).
Heimann, H.: Die Scopolaminwirkung. Basel-New York: Karger 1952.
— Ausdrucksphänomenologie der Modellpsychosen (Psilocybin). Psychiat. et Neurol. (Basel)
141, 69–100 (1961).
— Die Wirkung von ololiuhqui im Unterschied zu Psilocybin. Neuropsychopharmacology,
4, (ed. D. Bente and P. B. Bradley). Amsterdam-London-New York: Elsevier Publishing Co. 1965.
—, and G. Lukács: Experimentell-psychol. Differenzierung der Wirkung von zwei Psychostimulantien am Menschen. Psychopharmacologia (Berl.)
8, 79 (1965).
Hofmann, A., and A. Cerletti: Die Wirkstoffe der dritten aztekischen Zauberdroge. Dtsch. med. Wschr.
86, 885 (1961).
Isbell, H., and C. W. Gorodetzky: Effect of alkaloids of ololiuhqui in man. Psychopharmacologia (Berl.)
8, 331–339 (1966).
Osmond, H.: ololiuhqui: The ancient Aztec narcotic. J. ment. Sci.
101, 526 (1955).
Reko, V.: Magische Gifte. Stuttgart: Enke 1949.
Schmid, B.: Die psychische Wirkung von Ibogalin-Hydrochlorid. Arzneimittel-Forsch. (Drug Res.)
17, 485 (1967).
Schulthes, R. E.: A contribution to our knowledge of
Rivea corymbosa. The narcotic ololiuhqui of the Aztecs. Botanical Museums of Harvard University, Cambridge (Mass.) 1941.
Solms, H.: Chemische Struktur und Psychose bei Lysergsäurederivaten. Praxis
45, 746 (1956).
Prof. Dr. H. Heimann
Clinique Psychiatrique Universitaire
Hôpital de Cery
CH-1008 Prilly, Lausanne
Edgar Heim
Psychiatric University Polyclinic
CH-3000 Bern, Hügelweg 2
1: Since the conclusion of this study, we have also developed a quantitative method for the analysis of mimic movements (cf. Heimann and Lukács).
2: The compilation can be requested from the authors.
3: On this occasion we would like to once again extend our heartfelt thanks to all colleagues for their willingness and participation.
4: e.g. Psilocybin.
5: In a currently ongoing study we are testing the effect of d-lysergic acid hydroxyethylamide in a chemically stable form.